Topic: non-Hodgkin lymphoma
Allogene and Notch Therapeutics are teaming up to create off-the-shelf, stem cell-based treatments for blood cancers.
The cash will push a treatment for non-Hodgkin lymphoma into the clinic and support the development of Adicet’s gamma delta T-cell platform.
Transplanting T-cells to immunotherapies could lead to better results in non-Hodgkin lymphoma, Mount Sinai scientists have found.
IGM Biotherapeutics picked up $102 million in series C financing to work on its pipeline of cancer drugs.
ADC Therapeutics has expanded its series E by $76 million, extending its runway through the end of 2020.
The agreement gives Spectrum an antibody-interferon fusion technology drug delivery platform designed to generate oncology candidates.
Injecting a vaccine into tumor sites produced remissions in mice and some lymphoma patients in a study at Mount Sinai.
Phase 2b data showed TG Therapeutics’ umbralisib partially shrank tumors in 33% and eradicated them in 19% of marginal zone lymphoma patients.
Merck is making a $300 million move to acquire Immune Design, developers of a midphase immunotherapy for non-Hodgkin’s lymphoma.
Roche’s Rituxan and an anti-CD47 drug from Stanford shrank the cancers of half the patients in a phase 1 trial.